Gluetacs Therapeutics (Shanghai) Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moiety covalently linked to a Bruton tyrosine kinase (BTK) and eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) targeting moiety through a linker reported to be useful for the treatment of cancer, anemia, transplant rejection, neurodegeneration, infections, autoimmune, inflammatory and metabolic disorders.
Scripps Research Institute and Shangpharma Innovation have divulged cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoinflammatory interferonopathy, autoimmune and neurological disorders.
The University of Hong Kong has identified reactive oxygen species (ROS)-responsive prodrugs reported to be useful for the treatment of rheumatoid arthritis, cancer and hypertension.
Nido Biosciences Inc. has synthesized bicyclic compounds acting as selective androgen receptor modulators (SARMs) reported to be useful for the treatment of spinal and bulbar muscular atrophy, neurodegeneration and cancer.
Sichuan Haisco Pharmaceutical Co. Ltd. has disclosed AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of diabetic neuropathy and postherpetic neuralgia.
With China taking steps to enact or propose amendments to more than 60 intellectual property (IP)-related laws and regulations over the past few years, drug and device companies doing business in the country need to keep abreast of the changes. Despite China’s efforts, most of the participants in the Feb. 9 U.S. Patent and Trademark Office’s quarterly China IP webinar indicated in a pre-webinar survey that they have yet to see much of an improvement in China’s enforcement and regulation of IP rights.
Fox Chase Chemical Diversity Center Inc. has described novel bis-amide containing compounds reported to be useful for the treatment of fungal infections.
Japan's National Center for Global Health and Medicine (NCGM) has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).
Aphiotx Inc. has identified sulfamoyl benzene derivatives acting as pannexin-1 (PANX1; MRS1) inhibitors reported to be useful for the treatment of opioid withdrawal.
Sichuan Haisco Pharmaceutical Co. Ltd. has synthesized selective estrogen receptor degradation inducers (SERDs) reported to be useful for the treatment of cancer.
RSS
